1. Home
  2. SAGE vs MREO Comparison

SAGE vs MREO Comparison

Compare SAGE & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAGE
  • MREO
  • Stock Information
  • Founded
  • SAGE 2010
  • MREO 2015
  • Country
  • SAGE United States
  • MREO United Kingdom
  • Employees
  • SAGE N/A
  • MREO N/A
  • Industry
  • SAGE Biotechnology: Pharmaceutical Preparations
  • MREO Biotechnology: Pharmaceutical Preparations
  • Sector
  • SAGE Health Care
  • MREO Health Care
  • Exchange
  • SAGE Nasdaq
  • MREO Nasdaq
  • Market Cap
  • SAGE 413.9M
  • MREO 424.5M
  • IPO Year
  • SAGE 2014
  • MREO N/A
  • Fundamental
  • Price
  • SAGE $6.46
  • MREO $2.15
  • Analyst Decision
  • SAGE Hold
  • MREO Strong Buy
  • Analyst Count
  • SAGE 19
  • MREO 7
  • Target Price
  • SAGE $9.88
  • MREO $7.71
  • AVG Volume (30 Days)
  • SAGE 815.0K
  • MREO 943.2K
  • Earning Date
  • SAGE 04-29-2025
  • MREO 05-13-2025
  • Dividend Yield
  • SAGE N/A
  • MREO N/A
  • EPS Growth
  • SAGE N/A
  • MREO N/A
  • EPS
  • SAGE N/A
  • MREO N/A
  • Revenue
  • SAGE $47,404,000.00
  • MREO N/A
  • Revenue This Year
  • SAGE $103.73
  • MREO N/A
  • Revenue Next Year
  • SAGE $41.15
  • MREO $54.91
  • P/E Ratio
  • SAGE N/A
  • MREO N/A
  • Revenue Growth
  • SAGE N/A
  • MREO N/A
  • 52 Week Low
  • SAGE $4.62
  • MREO $1.58
  • 52 Week High
  • SAGE $13.47
  • MREO $5.02
  • Technical
  • Relative Strength Index (RSI)
  • SAGE 38.73
  • MREO 40.94
  • Support Level
  • SAGE $6.36
  • MREO $2.12
  • Resistance Level
  • SAGE $6.78
  • MREO $2.27
  • Average True Range (ATR)
  • SAGE 0.24
  • MREO 0.13
  • MACD
  • SAGE -0.01
  • MREO -0.02
  • Stochastic Oscillator
  • SAGE 12.22
  • MREO 9.09

About SAGE Sage Therapeutics Inc.

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Share on Social Networks: